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Abstract
A novel form of immune cell quantification in blood and tissue is described using epigenetic - based, quantitative
real-time PCR assisted cell counting (qPACC). The methylation status of the chromatin structure of either actively
expressed or silenced genes is the basis of the epigenetic-based cell identification and quantification technology.
Discovery of cell type specific removal of methyl groups (demethylation) from the 5′-carbon of the cytosine base in
the dinucleotide cytosine phosphate guanine permits precise and robust quantification of immune cells from only
small amounts of human blood or tissue samples. These epigenetic biomarkers located on genomic DNA are stably
associated with a cell type of interest.
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Description of the technology
All the different cell types that make up the human body
generally share the exact same deoxyribonucleic acid
(DNA). However, not all cells have the same function
and identity. Epigenomics is providing an explanation
through the study of the key functional components that
regulate gene expression in a cell. Despite having the
same DNA, sequence specific, epigenetic marks in each
cell type activate certain gene sequences and silence
others so that various progenitor cells can differentiate
into specialized cell types like muscle, liver, bone or
immune cells. These marks, like DNA methylation,
occur without changing the primary DNA sequence but
can be passed on as epigenetic imprint from cell to cell
as they divide [1]. The NIH Roadmap Epigenomics
Consortium performed an analysis of more than one
hundred human reference epigenomes and profiled
those for DNA methylation, DNA accessibility, histone
modification patterns and RNA expression. They estab-
lished global maps of regulatory elements and defined regu-
latory modules of coordinated activity as well as their likely
activators and repressors, thereby explaining how cell-
specific programs of gene expression are achieved and tran-
scriptional and translational control is ensured. These novel
data provide a valuable resource for understanding the role
of epigenomic information in gene regulation, cellular
differentiation and the relationships between cells and
tissues [1].
One of these epigenetic marks, the methylation status
of the chromatin structure of either actively expressed
or silenced genes, is the basis of the cell identification
and quantification technology described here. Epigenetic
differentiation is based on addition and removal of a me-
thyl group to the 5’-carbon of the cytosine base and oc-
curs exclusively in the dinucleotide cytosine phosphate
guanine (CpG). DNA methylation is a non-random
event and often associated with inactive gene expression,
if the target CpGs are located in the proximity of coding
regions. In contrast, demethylation of CpG in regulatory
elements is commonly accompanied by activation of
gene expression. Recent discovery of cell type specific
epigenetic CpG demethylation markers permits precise
and robust quantification of immune cells from only
small amounts of human blood or tissue samples [2].
These epigenetic biomarkers located on genomic DNA
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are stably associated with a cell type of interest [3]. The
first step, the epigenetic assay development phase, is
only necessary once for every cell type or subtype for
which an immune cell marker is being developed. Here,
different cell types of interest suitable for assay develop-
ment are identified by cell type and subtype-specific epi-
genetic marker regions during genome wide differential
CpG demethylation analyses of highly purified cell popu-
lations. The initial purification is performed by cell sort-
ing by flow cytometry (FACS) and based on consensus
markers from the literature defining an immune cell
type that an assay is being developed for. The demethyl-
ation status of every CpG position in DNA of a FACS
purified cell type of interest is compared against a library
of other reference cell types with known CpG methy-
lation status. The regions that are selected for the de-
velopment of a cell type specific epigenetic assay are
based on specific DNA sequences with digitally differen-
tial bisulfite conversion (BSC) properties between the
different cell types. This means the respective CpG dinu-
cleotides must be fully demethylated in the cell type of
interest and methylated in all other cell types. During BSC,
unmethylated cytosines convert to uracil, but methylated
cytosines do not change. Resulting determination of a cell
type specific demethylation status in relevant loci is the
basis for the development of segregating primer and probes.
The cell quantitation methodology of any developed assay
is based on quantitative real-time PCR (qPCR), targeting
those differentially demethylated CpG marker regions in
the genomic DNA after a bisulfite conversion step (see
Fig. 1).
The cell type specific qPCR assays are designed such
that only the demethylated DNA is amplified. This facili-
tates subsequent fast quantification of various leukocyte
and other cell populations in any given DNA containing
sample by simple qPCR.
Type of data obtained/readout
The final read out of epigenetic differentiation assays is
reported as percentage measured of cell type of interest
of all other cells in a sample or, in addition, as percent-
age compared to other cell types measured in parallel.
Representative examples of assays developed are based
on complete demethylation of the Treg cell-specific
demethylated region (TSDR) in regulatory T cells (Treg)
[2, 3], the demethylated region in the intergenic region
of CD3D/CD3G in T cells [4], or the demethylation
within the CCR6 locus in CCR6-positive cells [5]. Vari-
ous epigenetic immune cell biomarkers have been identi-
fied, characterized and validated for regulated studies to
maintain intra-assay ≤ 15 % CV and inter-assay ≤ 20 % CV,
including those for Treg, Th17, Tfh, CD4+, CD8+ and
CD3+ T cells, B cells, Monocytes, NK cells and granulo-
cytes. Methodology for data analysis and specific mathem-
atical models have been published and it has been
demonstrated that group differences in epigenetic data
can be detected reliably [6].
Limitations of the approach
It would be beneficial to identify more cell type specific epi-
genetic markers, including ones for additional subsets and
Fig. 1 Assay principle – BSC treated genomic DNA specific qPCR. a Only demethylated cytosines in the target cell type (i.e. CD4+ T-cells)
convert to uracil during bisulfite conversion (BSC). This allows BSC genomic DNA specific segregating primer and probes to bind and lead
to a qPCR product. b Methylated cytosines in non - target cells do not change during BSC treatment of genomic DNA leading to a primer
mismatch and no qPCR product
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differentiation stages of immune cells, especially activated
and differentiated T cell populations known to play critical
roles in tumor immunology and autoimmune diseases.
Epigenetic differentiation of immune cells that are de-
fined as effector versus memory T cells based on sur-
face markers in flow, as well as activated cells versus
exhausted T cells, would increase further the amount
of actionable information derived with these assays.
Types of samples needed and special issues
pertaining to samples
The inherent stability of DNA and its methylation marks
provides the distinctive advantage that epigenetic assays are
non-susceptible to common stability and sample shipment
logistics concerns of other comparable assays and technolo-
gies that often require intact, viable or functional cells from
blood and tissue samples. This permits a significantly
broader range of acceptable sample conditions that can
be collected by clinical sites. Shipment is straightfor-
ward since whole blood and fresh/frozen solid tissue
samples can be shipped on dry ice and FFPE can be
used after shipment at room temperature. The cur-
rently available assays cover the major leukocyte types
and can be evaluated in regulated, clinical studies re-
quiring a total of 2 ml or less whole blood for all
markers combined. The amount of sample required for
such studies is being lowered by a factor of 20 to about
100 μl for all available assays combined in the near fu-
ture. Frozen tissue material requires 250 μg to 1 mg
tissue to measure twelve markers, less for fewer
markers. The exact material needed is less defined
compared to blood since the number of cells, and
therefore the DNA content in tissue, varies signifi-
cantly by weight or volume.
Level of evidence
About 40 papers have been published describing and using
this epigenetic differentiation based cell identification and
quantification platform. Oncology has been an important
area. The ratio of Treg to CD3 cells (immunoCRIT) mea-
sured with this technology has been shown as a potential
marker for aggressiveness of solid tumors in colorectal,
bronchial, mammary and ovarian cancers [7]. Other investi-
gational fields include transplanation, type 1 diabetes, auto-
immune hepatitis, dermatitis, as well as allergy and asthma.
Common clinical trial applications of this technology are
monitoring cell-mediated imunity (CMI) during immune-
modulatory investigations for oncology and inflammatory
diseases. Treg and CD3 cell monitoring in peripheral blood
of MS patients in the SELECT study, a randomized,
double-blind, placebo-controlled phase 2 clinical trial of the
daclizumab high-yield process (DAC HYPE), is a recent ex-
ample of an autoimmune, inflammatory disease setting that
can be supported by this immune monitoring technology.
It demonstrated that Treg phenotype and lineage stability
can be maintained in the face of CD25 blockade [8]. An-
other example is measurements of CD3+, Treg (FoxP3)
and Th17 cells in samples of a Phase 2 study of etroli-
zumab (EUCALYPTUS trial), an investigational drug
for the treatment of ulcerative colitis (submitted for publi-
cation). Since the tests can be applied on both blood and
tissue, they allow standardized measurements and compari-
son of circulating and tissue-infiltrating immune cells offer-
ing an alternative to flow cytometry for peripheral blood
samples and immunohistochemistry (IHC) in solid tissues.
The technology has significant differentiation points to
flow cytometric-based methodologies, which are stand-
ard quantitative assays to monitor immunodynamics in
blood. For example, the epigenetic based assay allows
quick quantification and unambiguous differentiation of
true Tregs from transiently Foxp3 expressing, activated
effector T cells, which can be challenging and complex
with flow cytometry [2, 9]. So far, there is a limited
amount of data from clinical studies published. The
release of additional clinical study data and future
clinical studies are crucial to further validate the
potential application of this novel technology for
disease diagnosis and biomarker discovery for cancer
immunotherapy.
Abbreviations
BSC: Bisulfite conversion; CpG: Cytosine phosphate guanine;
DNA: Deoxyribonucleic acid; FFPE: Formalin-fixed paraffin-embedded tissue;
FACS: Flow cytometry; CMI: Cell-mediated immunity; immunoCRIT: Cellular
ratio of immune tolerance; IHC: Immunohistochemistry; qPCR: quantitative
real-time PCR; qPACC: quantitative real-time PCR assisted cell counting;
TSDR: Treg cell-specific demethylated region.
Competing interests
TOK is an employee of Epiontis GmbH, Berlin, Germany.
JDY declares that he has no competing interests.
Authors’ contributions
TOK drafted the manuscript and JDY helped to revise the manuscript.
Both authors read and approved the final manuscript.
Acknowledgments
This report was supported and enabled by the dedicated work and the
members of the Biomarkers Taskforce of the Society for Immunotherapy of
Cancer (SITC).
Author details
1Epiontis GmbH, Rudower Chaussee 29, 12489, Berlin, Germany. 2Immune
Monitoring Core, Ludwig Center for Cancer Immunotherapy, Memorial Sloan
Kettering Cancer Center, 1275 York Ave, Box 386, New York, NY 10065, USA.
Received: 7 August 2015 Accepted: 12 August 2015
References
1. Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, et al.
Integrative analysis of 111 reference human epigenomes. Nature.
2015;518:317–30.
2. Baron U, Floess S, Wieczorek G, Baumann K, Grutzkau A, Dong J, et al.
DNA demethylation in the human FOXP3 locus discriminates regulatory
T cells from activated FOXP3(+) conventional T cells. Eur J Immunol.
2007;37:2378–89.
Kleen and Yuan Journal for ImmunoTherapy of Cancer  (2015) 3:46 Page 3 of 4
3. Wieczorek G, Asemissen A, Model F, Turbachova I, Floess S, Liebenberg V, et
al. Quantitative DNA methylation analysis of FOXP3 as a new method for
counting regulatory T cells in peripheral blood and solid tissue. Cancer Res.
2009;69:599–608.
4. Sehouli J, Loddenkemper C, Cornu T, Schwachula T, Hoffmuller U, Grutzkau
A, et al. Epigenetic quantification of tumor-infiltrating T-lymphocytes.
Epigenetics. 2011;6:236–46.
5. Steinfelder S, Floess S, Engelbert D, Haeringer B, Baron U, Rivino L, et al.
Epigenetic modification of the human CCR6 gene is associated with stable
CCR6 expression in T cells. Blood. 2011;117:2839–46.
6. Schildknecht K, Olek S, Dickhaus T. Simultaneous statistical inference for
epigenetic data. PLoS ONE. 2015;10:e0125587.
7. Turbachova I, Schwachula T, Vasconcelos I, Mustea A, Baldinger T, Jones KA,
et al. The cellular ratio of immune tolerance (immunoCRIT) is a definite
marker for aggressiveness of solid tumors and may explain tumor
dissemination patterns. Epigenetics. 2013;8:1226–35.
8. Huss DJ, Mehta DS, Sharma A, You X, Riester KA, Sheridan JP, et al. In vivo
maintenance of human regulatory T cells during CD25 blockade.
J Immunol. 2015;194:84–92.
9. Kitagawa Y, Ohkura N, Sakaguchi S. Molecular determinants of regulatory T
cell development: the essential roles of epigenetic change. Front Immunol.
2013;4:106.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Kleen and Yuan Journal for ImmunoTherapy of Cancer  (2015) 3:46 Page 4 of 4
